U.S. Biotech Stock News

Franklin Resources, Inc. ( NYSE:BEN ) has announced that it will be increasing its periodic dividend on the 9th of...

Some Cencora, Inc. ( NYSE:COR ) shareholders may be a little concerned to see that the Senior VP, Lazarus Krikorian...

Halozyme Therapeutics recently received FDA approval for RYBREVANT FASPRO, co-formulated with its ENHANZE platform for advanced EGFR-mutated non-small cell lung cancer, and earlier this month secured a preliminary patent injunction in Germany against a rival subcutaneous product. Together with the addition of commercialization veteran Jim Lang to its board, these developments reinforce Halozyme’s positioning at the center of subcutaneous biologic drug delivery and IP protection. We’ll now...

Gold Royalty (NYSEAM:GROY) just closed a $90 million follow on equity offering at $4 per share, issuing 22.5 million new common shares. This represents a meaningful capital raise that immediately reshapes its growth runway. See our latest analysis for Gold Royalty. The equity raise caps a big year for the stock, with a roughly 230% year to date share price return and about 247% one year total shareholder return, signaling that momentum is clearly building as investors re rate its growth...

CareDx (CDNA) just moved to settle long running shareholder derivative lawsuits, tying the legal truce to a package of governance reforms that tighten oversight, disclosure practices, and compliance monitoring across the company. See our latest analysis for CareDx. The legal settlement and recent bylaw changes come as CareDx’s share price has climbed to about $19.45, with a 30 day share price return of 13.21% and a three year total shareholder return of 72.74%. This suggests improving...

In Q3 2025, Bilibili reported a net profit after earlier losses as stronger user engagement and higher advertising revenue lifted performance, while China’s Politburo shifted toward a moderately loose monetary policy to support domestic demand and technology investment for 2026. This combination of an earnings turnaround and a policy stance favoring digital consumption highlights how platform engagement and macro support may reinforce Bilibili’s role in China’s online entertainment...

Bread Financial Holdings (BFH) just saw Fitch assign a B minus rating to its new perpetual preferred stock, building on an earlier issuer upgrade to BB with a stable outlook that underscores improving credit quality. See our latest analysis for Bread Financial Holdings. The latest Fitch actions and a run of earnings beats seem to be feeding into sentiment, with the share price now at $78.0 and a strong 30 day share price return of 20.56 percent helping extend a 26.14 percent 1 year total...

In December 2025, Biohaven Ltd. reported at the ESMO Immuno-Oncology Congress that its Trop2-directed antibody drug conjugate BHV-1510, combined with Regeneron’s anti-PD-1 cemiplimab, showed encouraging safety and efficacy signals across several solid tumors, including non-small cell lung, endometrial, urothelial, and triple negative breast cancers. The early-stage data, including a confirmed objective response rate above half in evaluable patients and durable participation beyond six...

Analysts have just lifted earnings forecasts for ZTO Express (Cayman) (NYSE:ZTO) for this year and 2026, citing stronger parcel volumes, healthier revenue in core express delivery, and solid operational execution. See our latest analysis for ZTO Express (Cayman). Those upgraded earnings forecasts arrive after a solid run in the stock, with the 1 month share price return of 10.67 percent and year to date share price gain of 11.77 percent suggesting positive momentum. At the same time, the 3...

In mid-December 2025, Adaptive Biotechnologies announced two non-exclusive agreements with Pfizer to apply its T-cell receptor discovery platform to rheumatoid arthritis and to license its extensive TCR–antigen binding dataset for Pfizer’s AI and machine learning-driven drug discovery efforts. The deals underscore the commercial potential of Adaptive’s immune repertoire data, with the rheumatoid arthritis collaboration alone carrying up to about US$890 million in possible milestones...

In recent days, multiple research firms including Truist Securities, Goldman Sachs, Citigroup, Barclays and Stifel reiterated positive views on Parker-Hannifin, signaling broad analyst confidence in the company’s operational and earnings outlook. This cluster of reaffirmed positive ratings and upgraded opinions effectively acts as a sentiment catalyst, spotlighting Parker-Hannifin as a preferred name among large-cap industrial and aerospace suppliers. Next, we’ll examine how this wave of...

Aptiv (NYSE:APTV) just expanded its automation ambitions by teaming up with Vecna Robotics to co develop autonomous mobile robots that aim to provide safer, more efficient material handling and a fresh avenue for long term growth. See our latest analysis for Aptiv. The Vecna Robotics tie up lands after a solid year to date share price return of roughly 30 percent, even though longer term total shareholder returns over three and five years remain negative. This suggests momentum is rebuilding...

Spyre Therapeutics (SYRE) just caught Wall Street’s eye, with firms like Mizuho and Citi initiating upbeat coverage that centers on its antibody pipeline for autoimmune and inflammatory diseases and upcoming clinical milestones. See our latest analysis for Spyre Therapeutics. Those upbeat notes are landing after a powerful run, with a 30 day share price return of roughly 38 percent and a 90 day share price return of around 118 percent. Meanwhile, the three year total shareholder return above...

Cipher Mining (CIFR) is suddenly on a lot more watchlists after locking in a multi billion dollar AI data center lease with Amazon Web Services, plus an expanded, Google backed Fluidstack hosting deal. See our latest analysis for Cipher Mining. Those AI infrastructure deals are arriving on the back of serious momentum, with a 30 day share price return of 14.56 percent and a year to date share price return of 235.61 percent. The three year total shareholder return of 2,901.85 percent shows how...

Relay Therapeutics, Inc. recently presented a subset analysis of interim data from its first-in-human ReDiscover trial, highlighting zovegalisib’s efficacy and tolerability in heavily pretreated HR+/HER2- advanced breast cancer patients at the 2025 San Antonio Breast Cancer Symposium. The data showed consistent progression-free survival and response rates across challenging subgroups, such as prior SERD exposure and ESR1-mutated tumors, reinforcing interest in this allosteric PI3Ka...

NGL Energy Partners (NGL) has quietly pulled back about 3% over the past month after a huge run in the past 3 months, leaving many investors wondering whether this is a healthy pause or an early warning sign. See our latest analysis for NGL Energy Partners. That pullback comes after a powerful stretch, with the 90 day share price return of 51.27 percent and a one year total shareholder return of 101.7 percent signaling that momentum, while cooling near 9.50 dollars, is still very much...

Noble Corporation has entered definitive agreements to sell six jackup rigs and has recently moved its ultra-deepwater drillship Globetrotter I into the Black Sea, where it began preparing for a new drilling campaign ahead of year-end. At the same time, a JPMorgan downgrade highlighting concerns over delayed ultra-deepwater contracts and limited pricing power adds a fresh lens on Noble’s repositioning toward deepwater and ultra-harsh environment work. We’ll now examine how Noble’s decision...

Earlier in 2025, Masimo held its Investor Day and outlined a multi-year plan targeting 7%–10% revenue CAGR and about 30% operating margins by 2028, while also completing the sale of its Sound United consumer audio unit to Samsung’s Harman to sharpen its focus on core healthcare monitoring. The company also secured a very large US$634 million jury verdict in a patent dispute with Apple over blood-oxygen technology, though the outcome remains uncertain as Apple plans to appeal, adding both...

WillScot Holdings (WSC) is navigating a rough patch, with the stock down about 26% over the past six months as softer quarters and expectations for a roughly 5% revenue decline weigh on sentiment. See our latest analysis for WillScot Holdings. Despite appointing a new Chief Accounting Officer to steady the ship and sharpen execution, the stock’s roughly 43% year to date and one year share price and total shareholder returns show momentum has clearly faded as investors reassess growth and...

Enerpac Tool Group (EPAC) just posted a mixed first quarter, with earnings and revenue landing slightly below expectations as net income and sales slipped year over year despite healthy product demand. See our latest analysis for Enerpac Tool Group. The latest results land against a choppy backdrop, with Enerpac’s share price at $37.23 after a recent pullback and a 1 year total shareholder return of minus 15.61%. However, longer term 3 year and 5 year total shareholder returns of 47.77% and...

Asana (ASAN) is back in the spotlight after BTIG initiated coverage with a Neutral view, just as KeyBanc shifted to a more positive stance. This is putting fresh attention on the company’s leadership, strategy, and recent execution. See our latest analysis for Asana. Those mixed signals help explain why Asana’s 1 month share price return of 19.1% looks strong even as its year to date share price return and 1 year total shareholder return both remain firmly negative. This suggests momentum is...

Earlier this week, BrightSpring Health Services drew fresh attention from Wall Street as multiple research firms reiterated positive ratings on the company, citing confidence in its long-term earnings outlook and sector positioning. What stands out is how this cluster of upbeat analyst views, underpinned by expectations of above-industry earnings growth, has rapidly shifted sentiment toward BrightSpring’s prospects. Next, we’ll examine how this wave of bullish analyst commentary could...

Xencor (XNCR) has struggled this year, but the stock quietly jumped nearly 50% over the past quarter. This move is drawing fresh attention to whether its antibody platform and licensing deals might be mispriced by the market. See our latest analysis for Xencor. That surge sits against a tougher backdrop, with the share price down sharply year to date and the 1 year total shareholder return also negative. This suggests recent momentum reflects shifting expectations around pipeline risk rather...

EQT (EQT) just moved to retire all of its 7.5% Senior Notes due 2027, a roughly $496 million slug of debt, tightening its balance sheet at a moment when natural gas dynamics are shifting in its favor. See our latest analysis for EQT. That debt clean-up comes after a busy stretch for EQT, from exiting its Kodiak Gas Services stake to boosting financial flexibility ahead of expected LNG demand growth. The stock’s roughly 14% year to date share price return sits alongside a powerful five year...